Molecular targets in urinary bladder cancer
Open Access
- 10 May 2022
- journal article
- Published by Scientific Scholar in International Journal of Molecular and Immuno Oncology
- Vol. 7, 64-68
- https://doi.org/10.25259/ijmio_4_2022
Abstract
Molecular classification of urothelial carcinoma of the bladder has revealed high mutation rates and a heterogenous variety of mutations. FGFR3 mutations are commonly detected in the Luminal-papillary subtype. Molecular targeted therapy for urothelial carcinoma is now the standard of care after disease progression on platinum/immune checkpoint inhibitor therapy. Enfortumab vedotin is preferred as there is level 1 evidence available to support its use. Erdafitinib is the first approved gene-targeted therapy for patients with FGFR3/2 alterations. Sacituzumab govitecan shows promise in early phase trials. Further results from phase 3 trials are eagerly anticipated.Keywords
This publication has 23 references indexed in Scilit:
- Comprehensive Molecular Characterization of Muscle-Invasive Bladder CancerCell, 2017
- The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancerOncotarget, 2017
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial CarcinomaThe New England Journal of Medicine, 2017
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trialThe Lancet Oncology, 2017
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialThe Lancet, 2016
- The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder TumoursEuropean Urology, 2016
- Enfortumab Vedotin Antibody–Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer ModelsCancer Research, 2016
- High expression of TROP2 correlates with poor prognosis in pancreatic cancerBritish Journal of Cancer, 2008
- Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder CancerJournal of Clinical Oncology, 2005
- Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III StudyJournal of Clinical Oncology, 2000